Garmin watches with a Dexcom g6 transmitter


Download

With Dexcom announcing a big new agreement with Garmin this month, it seemed like a good time to check in on a few issues. Stacey talks with Dexcom’s Chief Technology Officer Jake Leach about Garmin, the upcoming Dexcom G7 and Dexcom One. She asks your questions on everything from G7 features to watch compatibility to the future and possible non invasive monitoring.

Just a reminder – the Dexcom G7 has not yet been submitted to the US FDA and is not available for use as of this episode’s release.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Previous episodes with Jake Leach: https://diabetes-connections.com/?s=leach

Previous episodes with CEO Kevin Sayer: https://diabetes-connections.com/?s=sayer

Check out Stacey’s book: The World’s Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

—–

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
—–

Get the App and listen to Diabetes Connections wherever you go!

Click here for iPhone      Click here for Android

Episode transcription below:

sponsors & partners


Real Good Foods logo

 

Stacey Simms  0:00

Diabetes Connections is brought to you by Dario Health. Manage your blood glucose levels increase your possibilities by Gvoke Hypopen the first premixed auto injector for very low blood sugar, and by Dexcom take control of your diabetes and live life to the fullest with Dexcom.

 

Announcer  0:20

This is Diabetes Connections with Stacey Simms.

 

Stacey Simms  0:26

This week Dexcom announced a big new agreement with Garmin this month seemed like a good time to check in on a few issues, including what happens to the watches and insulin pump systems that work with G6, when Dexcom G7 it’s the market.

 

Jake Leach  0:41

We’re already working with Tandem and Insulet. On integrating G7 with their products have already seen prototypes up and running, they’re moving as quickly as possible.

 

Stacey Simms  0:49

That’s Chief Technology Officer Jake leach who reminds us that the G7 has not yet been submitted to the US FDA. He answers lots of questions on everything from G7 features to watch compatibility to the future and possible non invasive monitoring. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Welcome to another week of the show are we so glad to have you here I am the host Stacey Simms, and we aim to educate and inspire about diabetes with a focus on people who use insulin. You know, my son Benny was diagnosed with type one right before he turned to my husband lives with type two diabetes. I don’t have diabetes, I have a background in broadcasting. And that is how you get the podcast. And when I saw the news about Garmin, and Dexcom. I knew you’d have some questions. And I thought this would be a good chance to talk about some of the more technical issues that we’re all thinking about around Dexcom. These days.

I should note that since I did this interview with CTO Jake Leach on October 19. And that’s exactly one week before this episode is being released that Dexcom released some new features for its follow app. I did cover that in my in the news segment. That was this past week, you’d find the link in the show notes. And as I see it for that news that release in the update, the big news there is that now there is a widget or quick glance on the followers home screen, it depends on your device, you know, Apple or Android, there’s no tech support, right from the follow up, and a way to check the status of the servers as well. And I think that last one should really be an opt in push notification. If the servers are down, you should tell me right, I shouldn’t have to wonder are the servers down and then go look, but that is the update for now. And again that came out after this interview. So I will have to ask those questions next time.

And the usual disclaimer Dexcom, as you’ve already heard, is a sponsor of the show, but they only pay for the commercial you will hear later on not for any of the content you hear outside of the ad. I love having them as a sponsor, because I love that Vinnie uses the product. I mean, we’ve used Dexcom since he was nine years old. But that doesn’t mean I don’t have questions for them. And I do give them credit for coming on and answering them. Not everybody does that. I should also add that this interview is a video interview, we recorded the zoom on screen stuff. You can see that at our YouTube channel. I’ll link that up in the show notes if you would rather watch and there always will be a transcript these days in the show notes so lots of options for however it suits you best. I’m here to serve let me know if there’s a better way for me to get this show to you. But right now we’ve got video audio and transcript. Alright Jake leach in just a moment.

But first Diabetes Connections is brought to you by Dario health and you know one of the things that makes diabetes management difficult for us that really annoys me and Benny, it’s not really the big picture stuff. It’s all the little tasks that add up. Are you sick of running out of strips do you need some direction or encouragement going forward with your diabetes management? Would visibility into your trends help you on your wellness journey? The Dario diabetes success plan offers all of that in more you don’t the wavelength the pharmacy you’re not searching online for answers. You don’t have to wonder about how you’re doing with your blood sugar levels, find out more, go to my dario.com forward slash diabetes dash connections.

Jake leach Chief Technology Officer for Dexcom thanks so much for joining me. How are you doing?

 

Jake Leach  4:22

I’m doing great, Stacey. It’s a pleasure to be here.

 

Stacey Simms  4:24

We really appreciate it. And we are doing this on video as well as audio recording as well. So if we refer to seeing things, I don’t think we’re sharing screens or showing product. But of course we’ll let everybody know if there’s anything that you need to watch or share photos of. But let me just jump in and start with the latest news which was all about Garmin. Can you share a little bit about the partnership with Garmin? What this means what people can see what’s different?

 

Jake Leach  4:49

Yeah, certainly so I’m really excited to launch the partnership with Garmin. So last week we released functionality on the Dexcom side and Garmin released their products, the ability to have real time CGM readings displayed on a whole multitude of Garmin devices by computers, and a whole host of their watches. So they’ve got a lot of different types of watches for, you know, athletics and different things. And so you can now get real time CGM displayed on that on that watch. So they’re the first partner to take advantage of some new technology that we got FDA approved earlier in the year, which is our real time cloud API. So that’s a a way for companies like Garmin to develop a product that can connect up to users data through the Dexcom, secure cloud and have real time data, we’ve had the capability to do that with retrospective data that three hour delayed, many partners are taking advantage of that. But we just got the real time system approved. And so Garmins, the first launch with it.

 

Stacey Simms  5:50

Let me back up for just a second for those who may use these devices, but aren’t as technologically focused. What is an API? When you got approval for that earlier in the summer for real time API? What does that what does that mean? Yeah, so

 

Jake Leach  6:03

it’s a API is an application programming interface. And so what it really means is, it’s a way for software applications, like a mobile app on your phone, to connect via the Internet to our cloud with very secure authentication, and pull your CGM data in real time from from our cloud. And so it’s basically a toolkit that we provide to developers of software to be able to link their application to the Dexcom application, and really on the user side, to take advantage of that feature, you basically enter in your Dexcom credentials, your Dexcom username and password. And that is how we securely authenticate. And that’s how you’re basically giving access to say, for example, Garmin, to pull the data and put it down onto your devices. What other

 

Stacey Simms  6:51

apps or companies are in the pipeline for this. Can you share in addition to Garmin? I think I had seen Livongo Are there others?

 

Jake Leach  6:58

Yeah, so Livongo so Tela doc would purchase the Lubanga technology, they’ve got a system. They’re also in the pipeline for pulling in real time CGM data into their application. And so they’re all about remote care. And so trying to connect people with physicians through, you know, technology, and so having real time CGM readings in that type of environment is a really nice use case for them. And so and for the for the customers. And so that’s, that’s where they’re headed with it. And we’ve got kind of a bunch more partners that are in discussions in development that we haven’t announced yet. But we’re really see this, the cloud API’s are interfaces as a way to expand the ecosystem around a Dexcom CGM. So we really like to provide our users with choice. So how do you want your data displayed? Where do you want it? And so if you want to right place, right time for myself, have a Garmin bike computer so I can see CGM readings right on my handlebars, I don’t have to, you know, look down on a watch or even thought phones, it’s really convenient. That’s what we’re about is providing an opportunity for others to amplify the value of CGM.

 

Stacey Simms  8:06

This was a question that I got from the listener. What happens to the data? Is that a decision up to a company like Garmin, or is that part of your agreement, you know, where everybody’s always worried about data privacy? And with good reason?

 

Jake Leach  8:19

Yeah, data privacy is super important area when when you’re handling customer information. And so the way that it works is, when you’re using our applications at the beginning, when you sign up, there’s some consents, you’re basically saying this is what can be done with my data. And the way we design our systems is, for example, with the connection to the Garmin devices, the only way they can access your data is if you type in your credentials into there, it’s like it’s almost like typing your username and password into the web to be able to access your bank account. It’s the same thing, you’re granting access to your data. And each company has their own consents around data. And so we all are required by regulatory agencies to stay compliant with all the different rules to Dexcom. We take it very seriously, and are very transparent about what happens with the data that’s in we keep it in all of our consent forms that you click into as you as you work through the app.

 

Stacey Simms  9:13

But to be clear to use the API or to get the Dexcom numbers on your garmin, you said earlier, you have to enter your credentials,

 

Jake Leach  9:19

you have to you have to enter your Dexcom username and password. And that’s how we know that it’s okay for us to share that information with Garmins system because you are the one who authorized it.

 

Stacey Simms  9:30

Right. But that’s also how you were going to use it. You just said you have to enter your name and password for them to use the information. So they just have to read individually like okay, Garmin or Livongo or whomever. Yes. Your individual terms of services.

 

Jake Leach  9:42

Yeah, for each each application that that you want to use you it’s important to read the what they do with the data and how to use it.

 

Stacey Simms  9:49

That’s really interesting. And Has anything changed with Dexcom? It’s been a long time since we’ve talked about how you all use the data. My understanding is that it was blinded, you know, you’re not turning around over to health insurers and saying yeah, done on this day this or are you?

 

Jake Leach  10:03

No, no, not at all, we basically use the information to track our product performance. So we look at products there. So it’s de identified, we don’t know whose product it was, we just can tell how products are performing in the field. That’s a really important aspect. But we also use it to improve our products. So we when we see the issues that are occurring with the use of the product, we use it to improve it. So that’s, that’s our main focus. And the most important thing we do with it is provided to users where, where and when they need it. So you know, follow remote monitoring that the reason we built our data infrastructure was to provide users with features like follow and the clarity app and so forth.

 

Stacey Simms  10:36

Do those features work on other systems? Can I use Garmin to share or follow?

 

Jake Leach  10:41

Not today? So right now, it’s, it’s basically intended for the the person who’s wearing the CGM. It’s your personal CGM credentials that you type in to link the Carmen account. And so for today, it’s specific around the user.

 

Stacey Simms  10:57

I assume that means you’re working on for tomorrow.

 

Jake Leach  10:59

There’s lots of Yeah, lots.

 

Stacey Simms  11:02

Which leads us of course to Well, I don’t have to worry about that right now. Because you can’t use any of this without the phone and the Phone is how we could share it follow. So it’s not really an issue yet. Jake, talk to me about direct to watch to any of these watches. Yeah, where do we stand? I know G6. It’s not going to happen. Where are we with G7?

Right back to Jake answering my question, you knew I was gonna bring that up. But first Diabetes Connections is brought to you by Gvoke Hypopen. And when you have diabetes and use insulin, low blood sugar can happen when you don’t expect it. That’s why most of us carry fast acting sugar and in the case of very low blood sugar, why we carry emergency glucagon, there’s a new option called Gvoke Hypopen the first auto injector to treat very low blood sugar Gvoke Hypopen is pre mixed and ready to go with no visible needle. In usability studies. 99% of people were able to give Gvoke correctly find out more go to diabetes connections.com and click on the Gvoke logo. Gvoke shouldn’t be used in patients with pheochromocytoma or insulinoma. Visit Gvoke glucagon.com/risk now back to Dexcom’s jake leach answering my question about direct to watch

 

Jake Leach  12:19

That’s a great question and a really exciting technology. So direct to watch is where through Bluetooth, the CGM wearable communicates directly to a display device like a watch. So today, G6 communicates to the phone and to insulin pumps in our receiver are the displays. With G7, what we’ve done is we’ve re architected the Bluetooth interface to be able to also in addition to communicating with an insulin pump or a receiver and your mobile phone, it can also communicate with a wearable device like a Apple Watch, in particular, but other watches have those capabilities, with G7, reducing the capability within the hardware to have the direct communication director watch. And then in a subsequent release, soon after the launch to commercial launches of G7, we’ll have a release where we bring the director watch functionality to the customers, there’s the Bluetooth aspect, which is really important, you got to make sure it doesn’t impact battery life and other things. But there’s also the aspect of when it is direct to watch, it becomes your primary display. And so being able to reliably receive alerts on the watch was something that initially in the architecture wasn’t possible. But as Apple’s come out with multiple versions of the OS for the watch, they’ve introduced capability for us, so that we can ensure you get your alerts when you’re wearing the watch. And so that was a really important aspect for us. And it’s also for the FDA to ensure that if that’s your main display, you’ve walked away from your phone, you have no other device to alert you that it’s going to be reliable. And so that’s exciting progress of last couple years with Apple making sure that can happen. You know,

 

Stacey Simms  13:56

we’re all excited for Direct to watch. Obviously, it’s a feature that many people are really clamoring for. But you guys promised it first with the G five in 2017. Do you all kind of regret putting the cart before the horse that way? Because my next follow up question is why should we believe you now?

 

Jake Leach  14:15

Yeah, you know, it Stacy’s a good question. So we are hand was kind of forced because Apple actually announced it before we did. So they basically said we’re opening up this capability on the watch to have the direct Bluetooth connectivity. And of course, we were excited to have someone like Apple talking about CGM on that kind of a stage. But then as we got into the details of actually making it work, we, you know, continually ran into another technical challenge after another technical challenge, and I totally agree. I wish it would have been two years later that they talked about at the keynote, but I’m comfortable that we’ve gotten past those types of issues. And so and it is built into G7. So we’ve got working systems and so it will introduce it rather quickly with G7

 

Stacey Simms  14:56

and to confirm G7 has been submitted for the CE mark Because the approval in Europe, but has not yet, as you and I are speaking today has not yet been submitted for FDA approval in the US.

 

Jake Leach  15:06

Yeah, we’re just we’re just finishing up our submission, we get some validations that we’re running on some of the new manufacturing lines to make sure we can build enough of these for all the customers, we want to focus to move over to G7 as quick as possible. And so we’ll we’ll submit you seven to the FDA before the end of this year,

 

Stacey Simms  15:22

just kind of building off what you mentioned about Apple and making these announcements or, you know, sometimes Apple lets news get out there. Because they I don’t know if they seem to enjoy it. I’m speculating. I don’t have any insight track at Apple. But I wanted to ask you, I don’t know if you can say anything about this. For the last year, every time I talk to somebody who’s not getting the diabetes community, but they’re on a technology podcast, or they’re, they’re hearing things about non invasive blood glucose monitoring, right, the Apple, Apple series seven or some watch this year, we’re supposed to have this incredible, non invasive glucose monitoring was gonna put Dexcom and libre out of business, it was gonna be amazing. Of course, it didn’t happen. But a bunch of companies are working on this. And Apple seems to be really happy to say maybe, or we’re working on it, too, is Dexcom listening to these things. I mean, obviously, they’re not here yet. They they are going to come. I’m curious if this is all you kind of happy to let that lay out their speculation. Or if you guys are thinking about anything like this in the future,

 

Jake Leach  16:17

we pay a lot of attention to non invasive technologies. We have a an investment component of our company that looks at you know, early stage startups. We also have many partnership discussions around CGM technologies. And so when it comes to non invasive, I think we’d all love to have non invasive sensors that are accurate and reliable. You know, for many, many years since I’ve been working on CGM, and many years before that, there has been attempts to make a non invasive technologies work. The challenge, though, is it’s just sensing glucose in the human body with a non invasive technology is not been proven feasible. It’s just there’s a lot of different attempts and technologies have tried, and we pay close attention. Because if if something started to show promise, we become very interested in it. And basically making a Dexcom product that uses it, we just haven’t seen anything that is accurate and reliable enough for what our customers need. That’s to say, there could be a use case where a non invasive sensor doesn’t have to be as accurate and reliable as what what Dexcom does. And so maybe there’s a product there. But we’re very focused on ensuring that the accurate, the numbers that we show, the glucose readings that we present to users are highly accurate, highly reliable, that you can trust them. And so when it comes to non invasive, we just haven’t seen a technology that can do that. But I know that there’s lots of folks out there working on it. And we’re, we stay very close to the community.

 

Stacey Simms  17:40

Yeah, one of the examples I gave a guy who doesn’t he does an Apple technology podcast, and he was like, you know, what, what do you think? And I said, Well, here’s an example. He would a scale, and you have no idea if it’s accurate. But you know, that once you step on it that that number probably is is stable, then you know, okay, I gained 10 pounds, I lost 10 pounds. But I have no idea if that beginning number makes any sense at all, you might be able to use that if you are a pre diabetic, or if you’re worried about blood glucose, but you could never dose insulin using it because you have no idea where you’re starting. So I think that’s I mean, my lay person speculation. I think that’s where that technology is now and to that point, but other people outside the diabetes community are looking to one of the more interesting stories, I think, in the last year or two has been use of CGM and flash glucose monitoring for people without diabetes at all, for athletes, for people who are super excited and interested in seeing what their body’s doing. So we have companies like levels and super sapient. And you know, that kind of thing using the Liebreich. I’m curious of a couple of parts of this question. If you think you want to answer it is Dexcom. Considering any of those partnerships with the G7, which is much more simple, right? fewer parts and that kind of thing.

 

Jake Leach  18:46

Yeah, that’s a great point, Stacey. So yes, G7 is a lot simpler. It was designed to be to take the CGM experience to the next level. And part of that is just the ease of use the product deployment the simplicity, someone who’s never seen a CGM before, we want to be able to walk up approach G7 And just use it. There’s a lot of opportunity we feel for glucose sensing outside of diabetes. Today CGM are indicated for use in diabetes, but in the future, with 30% of the adult population in the US having pre diabetes, meaning the glucose levels are elevated, but not to the point where they’ve been diagnosed with diabetes. There’s just so much opportunity to help people understand their blood sugar and how it impacts lifestyle choices impact their blood sugar. In the immediate feedback you get from a CGM is just a there’s nothing else like it. And so I think, you know, pre diabetes and even as you mentioned, kind of in athletics. There’s a lot of research going on right now in endurance athletes, and in weight loss around using CGM readings for those different aspects. So I think there’s a lot opportunity we’re today we’re focused on diabetes, both type one and type two and really getting technology to people around the globe. That can benefit from it. That’s where our focus is. But we very much have programs where we look at, okay, where else could we use CGM? It’s such a powerful tool, you could think in the hospital, there’s so much opportunity around around glucose. Alright, so I’m

 

Stacey Simms  20:13

gonna give you my idea that I’ve given to the levels people, and they liked it, but then they dropped off the face of the earth. So I’ll be contacting them again. Here’s my idea. If somebody wants to pay for a CGM, and they don’t have diabetes, but they’re like paying out of pocket because they like their sleep tracker, and they like this and they like that, or some big companies gonna buy it and give it away for weight loss or whatever. You know, the the shoe company toms, where you buy a pair of shoes and they give one away. People are in the diabetes community are scrimping and saving and doing everything they can to get a CGM. Maybe we could do a program like that. Where if you don’t quote unquote medically need a CGM. Your purchase could also help purchase one for an underserved clinic that serves people with diabetes.

 

Jake Leach  20:54

Getting CGM to those folks that didn’t need them, particularly underserved areas, clinics. It’s so important. I like the idea. It’s a that’s if there was a cache component that then provided the CGM to those that are less fortunate. I think that’s, I like the idea. Next month is National Diabetes Awareness Month. And one of the things we’re focused on for the month of November is how can we bring broader access to CGM? It’s something we’ve been working on, you know, since we had our first commercial product, and there’s still, you know, many people in the United States benefit, you know, 99% of in private insurance covers the product. You know, a lot of our customers don’t pay anything, they have no copay. But you know, that’s not the case for everybody. And so there’s, there’s definitely areas that we need to we are focusing on some of our non profit partners on bringing that type of greater access to CGM, because it’s such a powerful tool and helping you live a more normal life.

 

Stacey Simms  21:50

In the couple of minutes that we have left. I had a couple more questions, mostly about G7. But you mentioned your hospital use. And last year, I remember talking to CEO Kevin Sayer about Dex comes new hospital program, which I believe launched during COVID. Do you have any kind of update on that or how it’s been going?

 

Jake Leach  22:06

Yeah, so it was a authorization that we got from the FDA to raise special case during COVID, to be able to use G6 in the hospital. And so we had quite a few hospitals contact us early on in COVID, saying, Hey, we’ve got these patients, many of them have diabetes, they’re on steroids. They’re in the hospital, and we’re trying to manage their glucose. And we’re having a hard time because their standard of care in hospitals is either labs or finger sticks. And so we got this authorization with the FDA, we ship the product, many hospitals acquired it, and they were using it pretty successfully. What we’d say about G6 is really designed for personal use your mobile phone or a little receiver device, designed integrated with a hospital patient monitoring system or anything like that. You could imagine in the future that that could be a real strong benefit for CGM, the hospital, you can imagine you put it on, you know, anybody who has glucose control issues comes in the door. And then you basically can help ensure where resources need to be directed based on you know, glucose risk. I’ve always been passionate about CGM at a hospital. It’s one of the early projects I worked on here. Dexcom. And I think it there’s a lot of promise, particularly as we’ve improved the technology. So there’s still hospitals today using G 600 of the authorization. And we’re interested in designing a product for that market specifically, instead of right now. It’s kind of under emergency years. But we think there’s there’s a great need there. That CGM could could help in basically glucose control in the hospital.

 

Stacey Simms  23:28

That’s interesting, too. Of course, my mind being a mom went to camp as well. Right? If you could have a bunch of people I envision like a screen or you know, hospital monitoring that kind of thing. You wonder if you could do something at camp where there’s 100 kids, you know, instead of having their individual phones or receivers at camp, it would be somewhere Central?

 

Jake Leach  23:46

Well, you know, what, between with the with the real time API, there are folks that are thinking about a camp monitoring system that can basically be deployed on campuses right now with follow. It’s great for a family, but it’s not really designed to, to follow a whole camp full of campers. But with the real time API, there’s opportunities for others to develop an application that could be used like that. So yeah, there you go.

 

Stacey Simms  24:08

All right, a couple of G7 questions. The one I got mostly from listeners was how soon and I know, timelines can be tricky. But how soon will devices that use the G6? Will they be able to integrate the G7 Insulin pumps, that sort of thing? Sure. It’s only Tandem right now. But you know, Omnipod, soon that that kind of thing?

 

Jake Leach  24:26

Yeah, I mean, that’s coming. So I’ll start with the digital partners like Garmin and others, that is going to be seamless, because the infrastructure that G6 utilizes to move data to through the API’s is the same with G7. So that’ll be seamless. When you talk about insulin pumps, so those are the ones that are directly connected to our transmitters that are taking the glucose readings for automated insulin delivery. So those systems were already working with Tandem and Insulet. On integrating G7 with their products have already seen prototypes up and running so they’re moving as quickly as possible. So once We have G7 approved, then they can go in and go through their regulatory cycle to get G7 approved for us with their AI D algorithms. Really the timing is dictated mainly by those partners and the FDA, but we’re doing everything we can to support them to ensure this as quick as possible.

 

Stacey Simms  25:17

Take I should have asked at the beginning, I’m so sorry, do you live with type one I’ve completely forgotten.

 

Jake Leach  25:21

I don’t I made a reference to where I wear them all the time. Because, as you know, kind of leading the r&d team here, I love to experience the products and understand what our users what their experience is. And I just love learning about my glucose readings in the different activities I do. So I don’t have type one. But I just I use the products all the time.

 

Stacey Simms  25:42

So to that end, have you worn the G7? And I guess I’d love to know a little bit more about ease of use. It looks like it’s, it just looks like it’s so simple.

 

Jake Leach  25:51

It is. Yeah. So I’ve participated in a couple of clinical trials where we use G7, it is really simple. One of the most exciting things though, I have to say is that when you put it on, it has this 30 minute warmup. So the two hours that we’ve all been used to for so many years, by the time you put the device on and you have it paired your phone, it’s there’s like 24 minutes left before you’re getting CGM. So it’s like it’s it. That part is just one of the things that you it sounds awesome. But then when you actually experience it, it’s pretty amazing. But yeah, the ease of use is great, because it’s the applicator is simple. It’s a push button like G sex where you just press the button and it deploys. But there’s other steps where you’re not having to remove adhesive liners, the packaging is very, very small. So we really focused on low environmental footprint. And so it’s really straightforward. But probably the most the really significant simplification the application process is because the transmitter and the sensor all one component and sterilized and saying altogether, there’s no pieces, there’s no assembly required, you basically take the device and apply it and then it’s up and running. There’s no transmitted a snap in or two pieces to assemble before you you do the insertion.

 

Stacey Simms  26:59

I think I know the answer to this. But I wanted to ask anyway, was it when you applied for the CE mark? And I assume this would be the same for the FDA? Are there alternate locations? In other words, can we use it on our arms?

 

Jake Leach  27:11

And yeah, that is that is a great question. Yeah, our focus with one of our phones with G7 and the revised form factor, the new new smaller form factor and sensor probe was arm were so yeah, arm wears is really important part of the G7 product.

 

Stacey Simms  27:26

I got a question about Dexcom. One, which seems to be a less expensive product with fewer features that’s available in Europe. Is that what Dexcom? One is?

 

Jake Leach  27:34

Yeah, so there’s a product that we recently launched in Europe in European countries. That is it’s called Dexcom. One. And what it is, is it’s it’s a product that’s designed for a broad segment of diabetes, type one, type two, it’s a lower price point. It has a reduced feature set from G6. But what it’s really about is simplicity. And so in you know it’s a available through E commerce solutions. So it’s really easy to acquire the product and start using it. It’s really to get into certain markets where we either weren’t didn’t have access to certain customers. And so it’s really designed for get generating access for large groups of people that didn’t have access to CGM before.

 

Stacey Simms  28:20

What does e commerce solution mean? No doctor

 

Jake Leach  28:23

there. So outside the United States CGM isn’t no prescription required for many, many countries. So the US is one of the countries that does require prescriptions, other some other countries do too. But there’s a large group outside the US that don’t, but it’s really around, you can basically go to the website, and you can purchase it over a website. So really kind of nice solution around think Amazon, right. You’re going you’re clicking on add the sensors and you’re purchasing it. It’s a exciting new product for us that we are happy to continue developing.

 

Stacey Simms  28:53

I think it might come to the US don’t know. Yeah, that’s

 

Jake Leach  28:56

good. Good question. Don’t don’t know. I mean, I think right now we see CGM coverage is so great access is great for CGM in the US it can always be better and extend your focus on that. But it’s really for countries where there wasn’t access,

 

Stacey Simms  29:08

I would think tough to since we do need a prescription differently. Yeah, Jake, you have been with Dexcom, almost 20 years, 18 years now. And a lot has changed. When you’re looking back. And looking forward here at Dexcom. I don’t really expect you to come up with some words of wisdom off the top of your head. But it’s got to be pretty interesting to see the changes that the technology has brought to the diabetes community and how I don’t know it just seems from where I sit and you’re probably a couple of years ahead. It seems that the last five years have just been lightspeed. It has

 

Jake Leach  29:39

been things are speeding up in terms of our ability to bring products to market and there’s a lot of things one is the development of technology. The other component is working with your groups like the FDA on you know, how do we get products to the customers as fast as possible and that that’s been a big part of it right moving cheese six to class to becoming an IC GM that That was a huge part of our ability to get the technology out quickly and also scale it. I think there’s a lot of aspects that has been faster. And you know, when I started Dexcom, we had this goal of designing a CGM that was reliable didn’t require finger sticks that could make treatment decisions. All that and we were 100% focused on that. And as we got closer and closer, and now we have that which you six and also what you seven, then the opportunity that that product can provide, you start to really understand how impactful CGM can be around the world. And that’s what I’m excited about now is I’m still excited about the technology always will be and we still have lots to do on making it better, more reliable and more integrated. But just how much CGM can do around around the globe. There’s just so many things. It’s beyond diabetes to so very excited about the future.

 

Stacey Simms  30:47

Many thanks, as always, and we’ll talk soon, I am sure but I mean, I could never get to say it enough. I can’t imagine doing the teenage years with my son without Dexcom. You guys, I know you did it just for me. You did it just in time. Appreciate it very much. He is doing amazing. And I can’t he would not be sticking his fingers 10 times a day. So thank you.

 

Jake Leach  31:05

That’s great to hear. Thanks, Stacy.

 

Announcer  31:12

You’re listening to Diabetes Connections with Stacey Simms.

 

Stacey Simms  31:18

As always more information at diabetes connections.com. And yeah, but that last bit there, I can say nice things. I mean, I really do feel that way. And I can still ask not so nice questions. Like if you’re new, quite often, I will open up a thread in our Facebook group. It’s Diabetes Connections of the group to gather questions for our guests. And I did that here with Dexcom, there’s usually quite a lot of questions, I do have to apologize, I missed a big one. Because of the timing of the interview, I promise I will circle back around next time I talk to Dexcom. And that is all about the updates for iOS and for new phones, and how you know, sometimes Dexcom is behind the updates. What I mean by that is that they lag behind the updates. So you can go to the Dexcom website, I’ll put a link up for this for Dexcom products that are compatible in terms of which iOS and that kind of thing. And they are behind. And Dexcom will always say they’ve said very publicly that they are working hard to catch up. But I guess the question that a few people really wanted to know was why, you know, why do they lag behind? What can be done about that? So they know, but I think it would be a good question to ask. So Sarah and others. I appreciate you sending that question. And I apologize that I didn’t get to it this time around.

And I’ll tell you, you know, it’s not something we’ve experienced, but I think it has to do and I’m speculating here more with the phone with the the newness and the the model of the phone sometimes then for the updates, especially if you don’t have your updates on automatic. So I guess I’m kind of saying the same thing. But what I mean by that is Vinny, and I have very old phones. I have an eight. I’m not even sure he has the eight. We are terrible parents and I don’t care about my phone, I would still have a Blackberry if that were possible. So I can’t commiserate. I’m so embarrassed to even tell you that I can commiserate with the updates, because it’s just not something that we have done. Benny, definitely if he were here, trust me. It’s like his number. I would say it’s his number one complaint that it’s really high up on the list of complaints to the parenting department in our house. And yes, Hanukkah is coming. His birthday is coming. There will be some new phones around here. I’m doing an upgrade. I’m sure both of us have cracked phones. Were the worst. Oh, my goodness.

All right. Well, more to come in just a moment. But first Diabetes Connections is brought to you by Dexcom. And this is the ad I was talking about earlier in the interest of full disclosure. But you know, one of the most common questions I get is about helping kids become more independent. I get asked this all the time at conferences for virtual chats in my local group. These transitional times are tricky. And we’ve gone through this preschool to elementary elementary to middle middle to high school. I can’t speak high school to college yet, but you using the Dexcom really makes a big difference. For us. It’s not all about sharing follow, although that’s very, very helpful. Just think about how much easier it is for a middle schooler to look at their Dexcom rather than do four to five finger sticks at school, or for a second grader to just show their care teams a number. Here’s where I am right before Jim. At one point, Ben, he was up to 10 finger sticks a day, he didn’t have Dexcom until the end of fourth grade not having to do that made his management a lot easier for him. It’s also a lot easier to spot the trends and use the technology to give your kids more independence. Find out more at diabetes connections.com and click on the Dexcom logo.

I don’t know about you, but I am getting a ton of email already about Diabetes Awareness Month and that is November this time of year I usually get I’d say 120 emails that are not snake oil, right one in 20 emails that maybe make sense for something we want to talk about on the show here that I would share on social media and I’m just inundated with nonsense. So I hope you are not as well. But I gotta say Diabetes Awareness Month this year. I’ve been pulling in My local group and talking about what to do because usually I highlight a lot of people and stories and I’ll I’ll still do that, I think, but I got to tell you people are, um, you know, this, we’re all stressed out. And while it’s a wonderful thing to educate, I always think Diabetes Awareness Month is not for the diabetes community, right? We are plenty aware of diabetes, this is a chance to educate other people. And that’s why I like sharing those pictures and stories on my page, because the families then can share that with their people. And it’s about educating people who don’t have diabetes. But gosh, I don’t know this year, I’m going to be just concentrating on putting out the best shows that I can

I do you have a new project I mentioned last week that we’re going to be talking about in the Facebook group. By the time this airs, I will have the webinars scheduled in the Facebook group. So very excited about that. Please check it out. But what are you doing for Diabetes Awareness Month? If you’ve got something you’d like me to amplify, please let me know. You can email me Stacey at diabetes connections.com. Or you can direct message me on the social media outlet of your choice. We are at YouTube, Facebook, Twitter and Instagram. That’s where Diabetes Connections lives. I’m on Tik Tok, or Snapchat or Pinterest. Oh my gosh. All right. Well, that will do it for this week. Thanks as always to my editor John Bukenas from audio editing solutions.

Thank you so much for listening. I will be back on Wednesday. live within the news. Live on Facebook and now on YouTube as well. Until then, be kind to yourself.

Benny:

Diabetes Connections is a production of Stacey Simms media. All rights reserved. All wrongs avenged

Leave a Reply